• Innovative Company SHIONOGI

What's New

  • Show All
2017/02/22
“Mother to Mother SHIONOGI Project”—Mother & Child Support Project in Kenya Starting Educational Activities to Improve Healthcare for Mothers and Children at an Established Clinic
2017/02/08
Audio webcasting: Third Quarter of FY2016 Financial Results
2017/02/07
Shionogi to Announce Corporate Reorganization and Personnel Reassignment
2017/02/02
Financial Results for the Third Quarter of FY2016
2017/01/27
Shionogi Presents Results from a Phase3 Clinical Trial of S-524101 for Allergy Immunotherapy Treatment of Pediatric Perennial Allergic Rhinitis by House Dust Mite
2017/01/18
Participation in the global, multi-stakeholder collaboration, called Access Accelerated
2017/01/12
SHIONOGI ANNOUNCES POSITIVE TOP-LINE RESULTS FOR CEFIDEROCOL PIVOTAL cUTI CLINICAL TRIAL
2017/01/10
Notice Regarding Completion of Cancellation of Treasury Shares
2016/12/21
Shionogi Establishes Japanese Subsidiaries
2016/12/19
“Cymbalta® Capsules 20 mg•30 mg” (Serotonin-noradrenaline reuptake inhibitor) Approved for an additional indication of pain associated with osteoarthritis
2016/12/19
SHIONOGI AND PURDUE PHARMA ESTABLISH ALLIANCE FOR JOINT U.S. COMMERCIALIZATION OF NALDEMEDINE
2016/12/08
Notice of Completion of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)
2016/12/05
Notice Regarding the Status (Progress Report) of Acquisition of Own Shares (Acquisition of own shares pursuant to the provision of Article 165, Paragraph 2 of the Companies Act)